Clinicopathological Features and Prognoses of Patients With Splenic Metastases From Breast Cancer: A Single-Centre, Retrospective Study by Xiaofeng Xie MD, Mingrui Ma MD, Xue Bai BS, Jing Hu MD, Haijie Zheng MD, Xiongqi Guo BS, Jiayi Huang MD, Xuelian Chen PhD, Liping Chen BS, Xiaofeng Lan BS, Lin Song BS, Caiwen Du PhD

“…T1 and T2 stages were documented in 15 (83.3%) patients, whereas N2 and N3 were documented in 13 (62.2%). 14 (77.8%) patients were oestrogen receptor and/or progesterone receptor positive. A Ki-67 index ≥ 30% accounted for 72.2% (13/18) of cases, and all patients were histological grade II or III. …”
Get full text

Sparse Gene Coexpression Network Analysis Reveals EIF3J-AS1 as a Prognostic Marker for Breast Cancer by Xin Chen, Zuyuan Yang, Chao Yang, Kan Xie, Weijun Sun, Shengli Xie

“…One lncRNA, EIF3J-AS1, is significantly associated with clinicopathological characteristics, including tumor size, lymph node metastasis, estrogen receptor (ER), and progesterone receptor (PR) status. Kaplan–Meier survival analysis revealed that EIF3J-AS1, a downregulated lncRNA in breast tumor, is a potential prognostic marker for breast cancer. …”
Get full text

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities by Wen-yu Cai, Xin-xian Cai, Yi-ran Fei, Rui Ye, Ding-ming Song, Dan Hu, Wan-wan Zhang, Ming-fei Xia, Xiao-xiao Yang

“…Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). …”
Get full text

HER2-Positive Metaplastic Spindle Cell Carcinoma Associated with Synchronous Bilateral Apocrine Carcinoma of the Breast by Katsumi Kito, Toshiharu Maeda, Keiko Ninomiya, Atsuro Sugita, Teiri Sagawa, Kinya Matsuoka, Kousei Kinoshita, Naoki Hyodo, Nagisa Morita, Keizo Furuya

“…Both apocrine carcinomas were immunohistochemically negative for estrogen receptor (ER) and progesterone receptor (PgR), but diffusely positive for androgen receptor (AR), GCDFP-15, and HER2. …”
Get full text

Study on Clinicopathological Features and Risk Factors of Patients with Multiple Primary Breast Cancers and Thyroid Disease by Jie Li, Yonghong Liu, Jian Jin, Qingfeng Shi, Yanting Ji, Bo Zhang, Pengfei Hu

“…There was no statistical difference in the comparison of data on the estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2, and molecular typing between the observation group and the control group (P>0.05). (4) Logistic regression analysis showed that age, menopausal status, and nuclear proliferation antigen index were the high-risk inflammatory factors for combined thyroid lesions (P<0.05). …”
Get full text

Clinical Evaluation of the Diagnostic Role of MicroRNA-155 in Breast Cancer by Fatemeh Hosseini Mojahed, Amir Hossein Aalami, Vahid Pouresmaeil, Amir Amirabadi, Mahdi Qasemi Rad, Amirhossein Sahebkar

“…However, no relationship between miR-155 expression and the presence of lymph node involvement (p=0.15), HER2 (p=0.79), Ki-67 (p=0.9), progesterone receptor (p=0.54), and estrogen receptors (p=0.84) was found. …”
Get full text

Deep Learning and Radiomics in Triple-Negative Breast Cancer: Predicting Long-Term Prognosis and Clinical Outcomes by Cheng C, Wang Y, Zhao J, Wu D, Li H, Zhao H

“…Chen Cheng,1,&ast; Yan Wang,2,3,&ast; Jine Zhao,4,&ast; Di Wu,1 Honge Li,5 Hongyan Zhao1 1Department of Ultrasound, Lianyungang Traditional Chinese Medicine Hospital, Lianyungang, 222004, People’s Republic of China; 2Department of Ultrasound, Lianyungang Municipal Oriental Hospital, Lianyungang, 222046, People’s Republic of China; 3Department of Ultrasound, Xuzhou Medical University Affiliated Hospital, Lianyungang, Jiangsu, 222061, People’s Republic of China; 4Department of Ultrasound, Donghai County People’s Hospital, Lianyungang, Jiangsu, 222300, People’s Republic of China; 5Department of Ultrasound, the First People’s Hospital of Lianyungang, Lianyungang, Jiangsu, 222061, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Hongyan Zhao, Department of Ultrasound, Lianyungang Traditional Chinese Medicine Hospital, No. 160, Chaoyang Middle Road, Haizhou District, Lianyungang, 222004, People’s Republic of China, Tel +86 0518-85574003, Email zhaohongyanzhy01@126.comAbstract: Triple-negative breast cancer (TNBC) is a unique breast cancer subtype characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression in tumor cells. …”
Get full text

Quantitative expression of estrogen, progesterone and human epidermal growth factor receptor-2 and their correlation with immunohistochemistry in breast cancer at Uganda Cancer Ins... by Henry Wannume, Nixon Niyonzima, Sam Kalungi, Julius Boniface Okuni, Tonny Okecha, Edward Kakungulu, Steven Mpungu Kiwuwa, Geoffrey Waiswa, Sylvester Kadhumbula, Monica Namayanja, Martin Nabwana, Jackson Orem

“…The detection of Estrogen Receptor (ER), Progesterone Receptor (PR), and Human epidermal growth factor receptor 2 (HER-2) is important for the stratification of breast cancer and the selection of therapeutic modalities. …”
Get full text

Clinical utility of receptor status prediction in breast cancer and misdiagnosis identification using deep learning on hematoxylin and eosin-stained slides by Gil Shamai, Ran Schley, Alexandra Cretu, Tal Neoran, Edmond Sabo, Yoav Binenbaum, Shachar Cohen, Tal Goldman, António Polónia, Keren Drumea, Karin Stoliar, Ron Kimmel

“…Abstract Background Molecular profiling of estrogen receptor (ER), progesterone receptor (PR), and ERBB2 (also known as Her2) is essential for breast cancer diagnosis and treatment planning. …”
Get full text

Long-term trends in the incidence of male breast cancer and nomogram for predicting survival in male breast cancer patients: a population-based epidemiologic study by Aimin Huang, Daning Li, Zhe Fan, Jingfang Chen, Weidong Zhang, Wentao Wu

“…A total of 2,057 patients were included in the competing risk analysis, which identified factors like older age, estrogen receptor (ER) negative, progesterone receptor (PR) negative, and advanced AJCC stage as being associated with shorter survival. …”
Get full text

The Impact of p53 and Ki67 Expression in Endometrial Cancer and its Effect on Survival by Zekiye Sahin, Burak Bayraktar, Tugba Karadeniz, Muzaffer Sanci

“…RESULTS: The study included 140 patients who met the inclusion criteria, 60% (n=84) of whom had endometrioid type endometrial carcinoma and 40% (n=56) had non-endometrioid type endometrial carcinoma. Estrogen and progesterone receptor positivity was significantly higher in the endometrioid type endometrial carcinoma group (p<0.001 and p<0.001, respectively). …”
Get full text

Comparing the efficacy of different methods in assessing cervical stromal invasion in endometrial carcinoma: a retrospective study of 2,020 patients by Ying Yang, Ying Yang, Zhijun Ye, Zhijun Ye, Yifei Zhao, Yifei Zhao, Zhengyu Li, Zhengyu Li

“…CSI was associated with cancer antigen 125, myometrial invasion, adnexal invasion, parametrial invasion, lymph node metastasis, and progesterone receptor.ConclusionsMRI is relatively superior in assessing CSI, although diagnostic authenticity and consistency were unsatisfactory. …”
Get full text

Exploring the heterogeneity of HER2 gene status and expression in non-positive breast cancer patients: insights from immunohistochemistry and fluorescence in situ hybridization by Jingmin Zhong, Beibei Gao, Qingjie Wang, Jun He, Danjv Luo, Chen Zhang, Jun Fan, Xiu Nie

“…Our analysis revealed that HER2-low tumors exhibited fewer grade III tumors (39.74% and 55.65%, respectively, P = 0.005) and higher positivity for estrogen receptor (ER, 88.89% vs. 61.74%, P < 0.001) and progesterone receptor (PR, 84.62% vs. 57.39%, P < 0.001) compared to HER2-ZERO tumors. …”
Get full text

Enhanced preoperative prediction of breast lesion pathology, prognostic biomarkers, and molecular subtypes using multiple models diffusion-weighted MR imaging by Litong He, Feng Li, Yanjin Qin, Yuling Li, Qilan Hu, Zhiqiang Liu, Yunfei Zhang, Tao Ai

“…Notably, IVIM-D and DKI-MK values were significantly different between estrogen receptor (ER)-positive and ER-negative tumors. Progesterone receptor (PR)-positive cancers exhibited lower Mono-ADC, IVIM-D, DKI-MD, SEM-DDC, CTRW-Dm, and CTRW-α values, alongside higher DKI-MK value compared to PR-negative cancers (p < 0.05). …”
Get full text

The Association between ER, PR, HER2, and ER−/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database by Hong Yu Shao, Bao Tan Hao, Feng Xiao Gao

“…The available research on the association between estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), ER−/PR+ status, and the occurrence of lung cancer subsequent to breast cancer in patients (referred to as BC-LuC) had been limited. …”
Get full text

Predicting breast cancer prognosis using PR and PIK3CA biomarkers: a comparative analysis of diagnostic groups by Yuting Feng, Qingzhen Song, Lei Yan, Ruoqi Li, Mengqin Yang, Peng Bu, Jing Lian

“…Abstract Purpose To evaluate the prognostic significance of progesterone receptor (PR) expression and the PIK3CA mutation status in HR+/HER2 − breast cancer patients, with the goal of screening patients who may derive the greatest benefit from PI3K-targeted therapy. …”
Get full text

Upregulated SAE1 Drives Tumorigenesis and Is Associated with Poor Clinical Outcomes in Breast Cancer by Hong Liu, Jing Wang, Yunhai Li, Feng Luo, Lei Xing

“…The SAE1 overexpression was significantly associated with the tumor size, tumor-node-metastasis stage, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and whether or not it was a triple-negative BC. …”
Get full text

(<i>E</i>)-1-(3-(3-Hydroxy-4-Methoxyphenyl)-1-(3,4,5-Trimethoxyphenyl)allyl)-1<i>H</i>-1,2,4-Triazole and Related Compounds: Their Synthesis and Biological Evaluation as Novel Anti... by Gloria Ana, Azizah M. Malebari, Sara Noorani, Darren Fayne, Niamh M. O’Boyle, Daniela M. Zisterer, Elisangela Flavia Pimentel, Denise Coutinho Endringer, Mary J. Meegan

“…<b>Methods</b>: A panel of 29 compounds was synthesized and examined by a preliminary screening in estrogen receptor (ER) and progesterone receptor (PR)-positive MCF-7 breast cancer cells together with cell cycle analysis and tubulin polymerization inhibition. …”
Get full text

The expression of BHLHE22 in endometrial carcinoma: Associations with mismatch repair protein expression status, tumor-infiltrating immune cells, programmed death-ligand 1 and clin... by Lin-Yu Chen, Hsing-Yu Chen, Hung-Cheng Lai, Shiou-Fu Lin, Kuo-Chang Wen, Darmawi, Phui-Ly Liew

“…Results: Twenty-nine of 109 cases (26.6 %) had high BHLHE22 expression, which was associated with higher tumoral CD8, higher stromal CD68 and lower progesterone receptor (PR). Survival analysis of the TCGA dataset showed better overall survival in subgroups with high BHLHE22/high CD8, high BHLHE22/low M2 macrophage, and high BHLHE22/low myeloid-derived suppressor cell. …”
Get full text

Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study by Akif Doğan, Nurullah İlhan, Goncagül Akdağ, Sedat Yıldırım, Mustafa Seyyar, Zeynep Yüksel Yaşar, Hande Nur Erölmez, Heves Sürmeli, Buğra Öztosun, Özlem Nuray Sever, Hatice Odabaş, Mahmut Emre Yıldırım, Devrim Çabuk, Nedim Turan, Mahmut Gümüş

“…Additional factors associated with poorer outcomes included liver metastasis, progesterone receptor negativity, high tumor grade, and the concurrent use of fulvestrant with CDK4/6 inhibitors. …”
Get full text